Encore Neutral

K162826 · Rymed Technologies, LLC · FPA · Jun 15, 2017 · General Hospital

Device Facts

• Record ID: K162826
• Device Name: Encore Neutral
• Applicant: Rymed Technologies, LLC
• Product Code: FPA · General Hospital
• Decision Date: Jun 15, 2017
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 880.5440
• Device Class: Class 2

Intended Use

The Encore™ Neutral is intended for single patient use in intravenous and blood administrations and aspiration without the need for needles, thus eliminating the potential for needle-stick injuries during use. The Encore™ Neutral may be used with low pressure power injectors having a maximum pressure of 325 psi and a maximum flow rate of 10 mL/sec. The subject device does not have to be changed subsequent to use with a low pressure power injector.

Device Story

Encore™ Neutral is a disposable, luer-activated needleless IV connector for intravenous/blood administration and aspiration. Device features straight-through fluid pathway, zero dead space, neutral fluid displacement, and effective blood clearing. Used in clinical settings to connect IV lines/syringes without needles, reducing needle-stick risk. Compatible with ISO 594-compliant male luer slip/lock devices and low-pressure power injectors (up to 325 psi). MR Safe; contains no metallic/magnetic components. Healthcare providers operate device by connecting to IV access points; neutral displacement design prevents blood reflux into catheter tip upon disconnection, potentially reducing catheter-related bloodstream infections and occlusions.

Clinical Evidence

Bench testing only. Performance verified via ISO 594-1/2, ASTM F1608, ASTM F1980, and ISO 11137. Functional testing included activation force, flow rate, fluid displacement, back pressure, power injection (325 psi/10 mL/sec), microbial ingress (up to 7 days/300 activations), mechanical hemolysis, and blood clearing. Biocompatibility testing performed per ISO 10993-1, -4, -5, -10, and -11.

Technological Characteristics

Luer-activated needleless connector. Materials: Copolyester, MABS polymer, silicone rubber. Compliant with ISO 594-1/2 (luer taper). MR Safe. Sterilization: Gamma (SAL 10^-6). No BPA, DEHP, or natural rubber latex.

Indications for Use

Indicated for single patient use in intravenous and blood administration and aspiration without needles to prevent needle-stick injuries. Compatible with low pressure power injectors (max 325 psi, 10 mL/sec).

Regulatory Classification

Identification

An intravascular administration set is a device used to administer fluids from a container to a patient's vascular system through a needle or catheter inserted into a vein. The device may include the needle or catheter, tubing, a flow regulator, a drip chamber, an infusion line filter, an I.V. set stopcock, fluid delivery tubing, connectors between parts of the set, a side tube with a cap to serve as an injection site, and a hollow spike to penetrate and connect the tubing to an I.V. bag or other infusion fluid container.

Special Controls

*Classification.* Class II (special controls). The special control for pharmacy compounding systems within this classification is the FDA guidance document entitled “Class II Special Controls Guidance Document: Pharmacy Compounding Systems; Final Guidance for Industry and FDA Reviewers.” Pharmacy compounding systems classified within the intravascular administration set are exempt from the premarket notification procedures in subpart E of this part and subject to the limitations in § 880.9.

Predicate Devices

• InVision-Plus® Injection Ports (K991653)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol that resembles three stylized human profiles facing to the right, stacked on top of each other.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

June 15, 2017

RyMed Technologies, LLC Ms. Anna McCutchen Director of Ouality Assurance and Regulatory Affairs 6000 W. William Cannon Drive B300 Austin, Texas 78749

Re: K162826

Trade/Device Name: Encore™ Neutral Regulation Number: 21 CFR 880.5440 Regulation Name: Intravascular administration set Regulatory Class: Class II Product Code: FPA Dated: May 19, 2017 Received: May 23, 2017

Dear Ms. Anna McCutchen:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

{1}------------------------------------------------

forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely,

# Lori A. Wiggins -S6

Lori A. Wiggins, MPT, CLT Acting Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K162826

Device Name Encore™ Neutral

Indications for Use (Describe)

The Encore™ Neutral is intended for single patient use in intravenous and blood administrations and aspiration without the need for needles, thus eliminating the potential for needle-stick injuries during use.

The Encore™ Neutral may be used with low pressure power injectors having a maximum pressure of 325 psi and a maximum flow rate of 10 mL/sec. The subject device does not have to be changed subsequent to use with a low pressure power injector.

| Type of Use (Select one or both, as applicable) | |
|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| <span style="text-decoration: overline;">X</span> Prescription Use (Part 21 CFR 801 Subpart D) | <span style="text-decoration: overline;"> </span> Over-The-Counter Use (21 CFR 801 Subpart C) |

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the logo for RyMed Technologies, LLC. The logo consists of a black square containing a white clover on the left, followed by the text "RyMed" in a bold, sans-serif font. Below "RyMed" is the text "TECHNOLOGIES, LLC" in a smaller, sans-serif font. The logo is simple and professional, with a clear emphasis on the company name.

# 510(k) Summary

Summary provided per [21 CFR 807.92]- K162826

Date: June 9, 2017

Common Name:

| Submitter's Information: | RyMed Technologies, LLC<br>6000 W. William Cannon Drive<br>Building B, Suite 300<br>Austin, TX 78749<br>512-301-7334 |
|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | |
| Contact: | Anna McCutchen<br>Director of Quality Assurance and Regulatory Affairs<br>Phone: [phone] x 303<br>Fax: [phone]<br>E-mail: [e-mail] |
| Device Name/ Trade Name: | Encore™ Neutral |

Needleless IV Connector

Device Classification: Regulation Number: 880.5440, Class II Intravascular Administration Set Classification Product Code: FPA Panel: General Hospital Predicate Device: 510(k) Number: K991653 Device Name: InVision-Plus® Injection Ports Classification Product Code: FPA Regulation Number: 880.5540, Class II Applicant: RyMed Technologies, LLC

#### Description of the Device

The Encore™ Neutral is a luer activated needleless IV Connector that is disposable and for single patient use. It includes the following features:

- . smooth swabbable surface
- . tight seal integrity with no gaps or openings
- straight-through fluid pathway resulting in zero dead space ●
- 100% effective blood clearing
- neutral fluid displacement ●
- . low priming volume
- saline-only flush option
- . no clamping sequence or positive pressure syringe technique required

{4}------------------------------------------------

The Encore™ Neutral is a sterile single-use device which is provided individually packaged. The Encore™ Neutral is also provided bulk non-sterile, to be further processed (packaged and sterilized) by another manufacturer.

The Encore™ Neutral is available with an optional protective end cap attached to the male luer of the device.

The Encore™ Neutral is compatible with ISO 594 compliant male luer slip devices and male luer lock devices.

The Encore™ Neutral is composed of medical grade materials that are not made with Bisphenol A (BPA), di-2-ethylhexyl phthalate, diethylhexyl phthalate (DEHP) or natural rubber latex. The materials used have been subjected to and have passed biocompatibility testing per the latest ISO 10993 standards.

The Encore™ Neutral is MR Safe as it does not contain metallic, magnetic or metal components.

The Encore™ Neutral may be used with low pressure power injectors having a maximum pressure of 325 psi and a maximum flow rate of 10 mL/sec. The device does not have to be changed subsequent to use with a low pressure power injector. When used with a low pressure power injector, the Encore™ Neutral must be secured with other devices rated for pressures up to 325 psi with a luer lock connection.

### Indication for Use

The Encore™ Neutral is intended for single patient use in intravenous and blood administrations and aspiration without the need for needles, thus eliminating the potential for needle-stick injuries during use.

The Encore™ Neutral may be used with low pressure power injectors having a maximum pressure of 325 psi and a maximum flow rate of 10 mL/sec. The subject device does not have to be changed subsequent to use with a low pressure power injector.

### Substantial Equivalence

The Encore™ Neutral is substantially equivalent to the predicate device having similar indications for use, technological characteristics, and performance. Below is a device comparison between the Encore™ Neutral and the predicate device. In addition, RyMed Technologies, LLC has successfully conducted microbial ingress testing for up to 7 days or 300 activations, and sterilization, shelf life and packaging validations.

{5}------------------------------------------------

| Characteristics for Substantial Equivalence (SE) Determination | | |
|----------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Characteristic | Predicate Device (K991653) | Encore™ Neutral (subject device) |
| FDA Regulation | 21 CFR 880.5440<br>Intravascular Administration Set<br>Class II<br>Classification Product Code: FPA | 21 CFR 880.5440<br>Intravascular Administration Set<br>Class II<br>Classification Product Code: FPA |
| Indications<br>for Use | Intended for single patient use in<br>intravenous and blood administration and<br>aspiration without the need for needles,<br>thus eliminating the potential for needle-<br>stick injuries during use. | Intended for single patient use in<br>intravenous and blood administration and<br>aspiration without the need for needles,<br>thus eliminating the potential for needle-<br>stick injuries during use.<br>Device may be used with low pressure<br>power injectors having a maximum<br>pressure of 325 psi and a maximum flow<br>rate of 10 mL/sec. The subject device does<br>not have to be changed subsequent to use<br>with a low pressure power injector. |
| Design | The predicate device is a luer activated<br>needleless IV Connector<br>The predicate device is disposable and for<br>single patient use.<br>The predicate device consists of a straight-<br>through fluid pathway with zero residual<br>volume (dead space), a smooth surface and<br>is non-hemolytic (aspiration and injection). | The subject device is a luer activated<br>needleless IV Connector<br>The subject device is disposable and for<br>single patient use.<br>The subject device consists of a straight-<br>through fluid pathway with zero residual<br>volume (dead space), a smooth surface and<br>is non-hemolytic (aspiration and injection). |
| Materials of<br>Construction | The predicate consists of the following<br>medical grade material types:<br>Polycarbonate, polyethylene, polyisoprene,<br>silicone rubber | The subject device consists of the<br>following medical grade material types:<br>Copolyester, MABS polymer, silicone<br>rubber |
| Sterilization | The product Sterility Assurance Level<br>(SAL) is 10-6<br>Method: Gamma and/or Ethylene Oxide | The product Sterility Assurance Level<br>(SAL) is 10-6<br>Method: Gamma |

{6}------------------------------------------------

## Comparison

The following differences exist between the subject device and predicate device:

- The subject device indications for use includes use with power injection procedures
- The materials to construct the devices differ
- The subject device is validated for Gamma sterilization while the predicate device may be Gamma or Ethylene Oxide sterilized

The differences in the indications for use for the subject device device do not alter the intended use of the subject device. Both the subject device and predicate device are intended for intravenous and blood administration and aspiration.

The material differences between the subject device and predicate device do not adversely affect the safety and effectiveness of the subject device. All materials are medical grade and have passed biocompatibility testing.

### Non-Clinical Data- Performance Testing

RyMed Technologies, LLC performed design verification performance testing to verify, demonstrate and support the claim of substantial equivalence to the predict device. All testing was conducted on the final finished sterile device.

The following standards were utilized in evaluating the functionality of the Encore ™ Neutral:

- . ISO 594-1:1986, Conical fittings with a 6 % (Luer) taper for syringes, needles and certain other medical equipment -- Part 1: General requirements
- . ISO 594-2:1998 Second Edition, Conical Fittings with a 6% (Luer) Taper for Syringes, Needles and Certain Other Medical Equipment- Part 2 Lock Fittings (General Plastic Surgery/General Hospital)
- ASTM F1608-16, Standard Test Method for Microbial Ranking of Porous Packaging Materials (Exposure Chamber Method)
- ASTM F1980-16, Standard Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices
- AAMI/ANSI/ISO 11137-1: 2006/(R)2010, Sterilization of Health Care Products- Radiation- Part 1: . Requirements for Development, Validation and Routine Control of a Sterilization Process for Medical Devices
- AAMI/ANSV/ISO 11137-2:2013. Sterilization of Health Care Products- Radiation- Part 2: Establishing ● the Sterilization Dose

{7}------------------------------------------------

The following performance tests were conducted according to internal procedures. All testing met the predetermined acceptance criteria and support the substantial equivalence determination:

- Activation Force ●
- Flow Rate at Gravity ●
- Fluid Displacement
- Multiple Activations ●
- Back Pressure ●
- Extended Access (Snap Back) ●
- High pressure (static conditions)
- Power Injection 10 mL/sec with maximum pressure of 325 psi ●
- Microbial Ingress
- Mechanical Hemolysis- Injection and Aspiration
- Blood Clearing ●

#### Biocompatibility

The materials of construction for the subject device were evaluated according to ISO 10993-1:2009 Biological Evaluation of Medical Devices- Part 1: Evaluation and Testing within a Risk Management Process. All testing was conducted on the final finished sterile device. RyMed Technologies, LLC performed testing according to the following parts of the ISO 10993 Standard:

- . ISO 10993-4:2002, Biological Evaluation of Medical Devices- Part 4: Selection of Tests for Interaction with Blood
- ISO 10993-5:2009, Biological Evaluation of Medical Devices- Part 5: Tests for InVitro Cytotoxicity ●
- ISO 10993-10:2010, Biological Evaluation of Medical Devices- Part 10: Tests for Irritation and Skin Sensitization
- ISO 10993-11:2006-, Biological Evaluation of Medical Devices- Part 11: Tests for Systemic Toxicity ●

### Conclusion

It is concluded that based on performance data and biocompatibility testing conducted on the subject device along with the same intended use and similarities in indications for use and technological characteristics that the subject device is substantially equivalent to the predicate device.